Stock Scorecard
Stock Summary for Anixa Biosciences Inc (ANIX) - $3.26 as of 1/23/2026 7:06:03 PM EST
Total Score
9 out of 30
Safety Score
19 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ANIX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ANIX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ANIX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ANIX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ANIX (19 out of 100)
| Stock Price Rating (Max of 10) | 3 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 3 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 4 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for ANIX
Financial Details for ANIX
Company Overview |
|
|---|---|
| Ticker | ANIX |
| Company Name | Anixa Biosciences Inc |
| Country | USA |
| Description | Anixa Biosciences Inc. is a leading biotechnology company based in San Jose, California, focused on delivering innovative solutions for unmet medical needs in oncology and infectious diseases. The company boasts a diverse pipeline of therapies and vaccines powered by advanced technologies designed to enhance patient outcomes in complex health scenarios. With a strategic emphasis on high-impact areas within the biopharmaceutical sector, Anixa is poised to drive significant advancements in medical innovation and contribute positively to global health solutions. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 10/31/2025 |
| Next Earnings Date | 3/10/2026 |
Stock Price History |
|
| Last Day Price | 3.26 |
| Price 4 Years Ago | 4.25 |
| Last Day Price Updated | 1/23/2026 7:06:03 PM EST |
| Last Day Volume | 153,794 |
| Average Daily Volume | 425,647 |
| 52-Week High | 5.46 |
| 52-Week Low | 2.33 |
| Last Price to 52 Week Low | 39.91% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.02 |
| Sector PE | 103.82 |
| 5-Year Average PE | -10.73 |
| Free Cash Flow Ratio | 81.50 |
| Industry Free Cash Flow Ratio | 10.81 |
| Sector Free Cash Flow Ratio | 27.30 |
| Current Ratio Most Recent Quarter | 8.08 |
| Total Cash Per Share | 0.04 |
| Book Value Per Share Most Recent Quarter | 0.46 |
| Price to Book Ratio | 7.26 |
| Industry Price to Book Ratio | 49.92 |
| Sector Price to Book Ratio | 19.79 |
| Price to Sales Ratio Twelve Trailing Months | 481.54 |
| Industry Price to Sales Ratio Twelve Trailing Months | 37.80 |
| Sector Price to Sales Ratio Twelve Trailing Months | 21.86 |
| Analyst Buy Ratings | 3 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 33,376,700 |
| Market Capitalization | 108,808,042 |
| Institutional Ownership | 16.46% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.31% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 12.96% |
| Reported EPS 12 Trailing Months | -0.34 |
| Reported EPS Past Year | -0.35 |
| Reported EPS Prior Year | -0.39 |
| Net Income Twelve Trailing Months | -10,927,000 |
| Net Income Past Year | -10,927,000 |
| Net Income Prior Year | -12,554,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 1,244,000 |
| Total Cash Past Year | 1,244,000 |
| Total Cash Prior Year | 1,271,000 |
| Net Cash Position Most Recent Quarter | 1,244,000 |
| Net Cash Position Past Year | 1,244,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 15,161,000 |
| Total Stockholder Equity Prior Year | 19,998,000 |
| Total Stockholder Equity Most Recent Quarter | 15,161,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -7,173,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.21 |
| Free Cash Flow Past Year | -7,173,000 |
| Free Cash Flow Prior Year | -7,335,000 |
Options |
|
| Put/Call Ratio | 0.00 |
| Has Options | Options Chain |
| Liquidity Rating | None |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -0.19 |
| MACD Signal | -0.21 |
| 20-Day Bollinger Lower Band | 2.64 |
| 20-Day Bollinger Middle Band | 3.74 |
| 20-Day Bollinger Upper Band | 4.83 |
| Beta | 0.50 |
| RSI | 42.02 |
| 50-Day SMA | 3.31 |
| 150-Day SMA | 3.36 |
| 200-Day SMA | 3.54 |
System |
|
| Modified | 1/23/2026 5:15:07 PM EST |